糖尿病类型对慢性肢体威胁性缺血首次血运重建结局的影响
该研究回顾2005至2014年单中心因慢性肢体威胁性缺血行首次腹股沟下旁路或经皮腔内血管成形/支架的1294条肢体,按胰岛素依赖糖尿病、非胰岛素依赖糖尿病及无糖尿病分组。结果显示胰岛素依赖糖尿病患者伤口愈合更差、大截肢及再干预/大截肢/狭窄事件风险更高,尤其以经皮腔内血管成形/支架为首选术式时;非胰岛素依赖糖尿病长期死亡率较低。
要点
- 胰岛素依赖糖尿病与更差6个月伤口愈合(41% vs 49% vs 61%)及更高3年大截肢率(23% vs 11% vs 8%)相关。
- 胰岛素依赖糖尿病较无糖尿病大截肢风险比2.0(95%CI 1.1-4.1),RAS事件风险比1.4(95%CI 1.1-1.8)。
- 经皮腔内血管成形/支架首选者中胰岛素依赖糖尿病大截肢风险比4.1(95%CI 1.3-12.6),旁路首选者仅伤口愈合不全风险比2.0(95%CI 1.4-4.5)。
核心结论
- 胰岛素依赖糖尿病较无糖尿病围术期及长期死亡率相似,但伤口愈合不全、大截肢及RAS事件风险更高,尤其经皮腔内血管成形/支架首选时。
- 非胰岛素依赖糖尿病较无糖尿病长期死亡率更低且肢体不良事件少。
- 数据提示区分糖尿病类型的重要性,以及合适选择的胰岛素依赖糖尿病慢性肢体威胁性缺血患者旁路首选策略的潜在长期获益。
研究设计与样本
- 单中心回顾性队列,2005至2014年因慢性肢体威胁性缺血行首次腹股沟下旁路或经皮腔内血管成形/支架的1294条肢体(旁路646条,经皮腔内血管成形/支架648条)。
- 按术前用药分为胰岛素依赖糖尿病703条、非胰岛素依赖糖尿病262条、无糖尿病329条。
- 采用χ2、Kaplan-Meier及Cox回归分析伤口愈合、大截肢、RAS事件、主要肢体不良事件及死亡率。
主要发现
- 胰岛素依赖糖尿病患者较非胰岛素依赖糖尿病及无糖尿病更年轻(69 vs 73 vs 77岁,P < .001),组织缺损(89% vs 77% vs 67%,P < .001)、冠心病(57% vs 48% vs 43%,P < .001)及终末期肾病(26% vs 13% vs 12%,P < .001)比例更高。
- 围术期并发症包括死亡率(3% vs 2% vs 5%,P = .07)组间无差异,但6个月伤口完全愈合胰岛素依赖糖尿病显著更差(41% vs 49% vs 61%,P < .001)。
- 3年大截肢率胰岛素依赖糖尿病显著更高(23% vs 11% vs 8%,P < .001)。
- 多变量分析示较无糖尿病,胰岛素依赖糖尿病大截肢风险比2.0(95%CI 1.1-4.1),RAS事件风险比1.4(95%CI 1.1-1.8);经皮腔内血管成形/支架首选者分别为4.1(95%CI 1.3-12.6)和1.5(95%CI 1.1-2.2),旁路首选者仅伤口愈合不全风险比2.0(95%CI 1.4-4.5)。
- 非胰岛素依赖糖尿病较无糖尿病晚期死亡率更低(风险比0.7,95%CI 0.5-0.9)。
临床怎么用
- 对胰岛素依赖糖尿病慢性肢体威胁性缺血患者,应预期伤口愈合更慢、大截肢及RAS事件风险更高并加强随访。
- 经皮腔内血管成形/支架首选的胰岛素依赖糖尿病患者大截肢风险尤其突出,选择术式时需权衡。
- 合适选择的胰岛素依赖糖尿病患者,旁路首选策略可能带来长期获益,但需结合个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The effect of diabetes type and insulin dependence on short- and long-term outcomes after lower extremity revascularization for chronic limb-threatening ischemia (CLTI) warrants additional study and more targeted focus. We sought to address this paucity of information by evaluating outcomes in insulin-dependent and noninsulin-dependent patients after any first-time revascularization. METHODS: We reviewed all limbs undergoing first-time infrainguinal bypass grafting (BPG) or percutaneous transluminal angioplasty with or without stenting (PTA/S) for CLTI at our institution from 2005 to 2014. Based on preoperative medication regimen, patients were categorized as having insulin-dependent diabetes (IDDM), noninsulin-dependent diabetes (NIDDM), or no diabetes (NDM). Outcomes included wound healing; major amputation; RAS events (reintervention, major amputation, or stenosis); major adverse limb events; and mortality. Outcomes were evaluated using χ2, Kaplan-Meier, and Cox regression analyses. RESULTS: Of 2869 infrainguinal revascularizations from 2005 to 2014, 1294 limbs (646 BPG, 648 PTA/S) fit our criteria. Overall, our analysis included 703 IDDM, 262 NIDDM, and 329 NDM limbs. IDDM patients, compared with NIDDM and NDM patients, were younger (69 vs 73 vs 77 years; P < .001) and more often presented with tissue loss (89% vs 77% vs 67%; P < .001), coronary artery disease (57% vs 48% vs 43%; P < .001), and end-stage renal disease (26% vs 13% vs 12%; P < .001). Perioperative complications, including mortality (3% vs 2% vs 5%; P = .07), did not differ between groups; however, complete wound healing at 6-month follow-up was significantly worse among IDDM patients (41% vs 49% vs 61%; P < .001). IDDM patients had significantly higher 3-year major amputation rates (23% vs 11% vs 8%; P < .001). Multivariable analyses illustrated that compared with NDM, IDDM was associated with significantly higher risk of both major amputation and RAS events after any first-time intervention (hazard ratio, 2.0 [95% confidence interval, 1.1-4.1] and 1.4 [1.1-1.8], respectively). Similar associations between IDDM and both major amputation and RAS events were found in patients undergoing a PTA/S-first intervention (4.1 [1.3-12.6] and 1.5 [1.1-2.2], respectively), whereas IDDM in BPG-first patients was associated with only incomplete wound healing (2.0 [1.4-4.5]). Last, compared with NDM, NIDDM was associated with lower late mortality (0.7 [0.5-0.9]). CONCLUSIONS: Compared with NDM, IDDM is associated with similar perioperative and long-term mortality but a higher risk of incomplete wound healing, major amputation, and future RAS events, especially after a PTA/S-first approach. NIDDM, on the other hand, is associated with lower long-term mortality and few adverse limb events. Overall, these data demonstrate both the importance of distinguishing between diabetes types and the potential long-term benefit of a BPG-first strategy in appropriately selected IDDM patients with CLTI.
引用
- Darling JD, Bodewes TCF, Deery SE, et al. Outcomes after first-time lower extremity revascularization for chronic limb-threatening ischemia between patients with and without diabetes. J Vasc Surg. 2017. PMID: 28947228. doi:10.1016/j.jvs.2017.06.119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。